학술논문
Volumetric Analysis of Glioblastoma for Determining Which CpG Sites Should Be Tested by Pyrosequencing to Predict Temozolomide Efficacy.
Document Type
Article
Author
Hosoya, Tomohiro; Takahashi, Masamichi; Davey, Calvin; Sese, Jun; Honda-Kitahara, Mai; Miyakita, Yasuji; Ohno, Makoto; Yanagisawa, Shunsuke; Omura, Takaki; Kawauchi, Daisuke; Ozeki, Yukie; Kikuchi, Miyu; Nakano, Tomoyuki; Yoshida, Akihiko; Igaki, Hiroshi; Matsushita, Yuko; Ichimura, Koichi; Narita, Yoshitaka
Source
Subject
*METHYLGUANINE
*VOLUMETRIC analysis
*RECEIVER operating characteristic curves
*PYROSEQUENCING
*TEMOZOLOMIDE
*GLIOBLASTOMA multiforme
*METHYLATION
*
*
*
*
*
*
Language
ISSN
2218-273X
Abstract
The aim of the present study was to determine which individual or combined CpG sites among O6-methylguanine DNA methyltransferase CpG 74–89 in glioblastoma mainly affects the response to temozolomide resulting from CpG methylation using statistical analyses focused on the tumor volume ratio (TVR). We retrospectively examined 44 patients who had postoperative volumetrically measurable residual tumor tissue and received adjuvant temozolomide therapy for at least 6 months after initial chemoradiotherapy. TVR was defined as the tumor volume 6 months after the initial chemoradiotherapy divided by that before the start of chemoradiotherapy. Predictive values for TVR as a response to adjuvant therapy were compared among the averaged methylation percentages of individual or combined CpGs using the receiver operating characteristic curve. Our data revealed that combined CpG 78 and 79 showed a high area under the curve (AUC) and a positive likelihood ratio and that combined CpG 76–79 showed the highest AUC among all combinations. AUCs of consecutive CpG combinations tended to be higher for CpG 74–82 in exon 1 than for CpG 83–89 in intron 1. In conclusion, the methylation status at CpG sites in exon 1 was strongly associated with TVR reduction in glioblastoma. [ABSTRACT FROM AUTHOR]